I don’t understand the wider picture: is Gilead likely to reduce the price in rich countries once it’s been licensed as a generic drug to poor countries (medical tourism, yay!). Or will they keep aggressively gouging?

I guess it depends on when the patent expires?

And suddenly it will become 400$/month

Wow. $40 a year would be transformative.

currently costs around $28,000 a year in the United States

…